Cover Image
市場調查報告書

塵蟎過敏 : 開發平台分析

House Dust Mite Allergy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246018
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
塵蟎過敏 : 開發平台分析 House Dust Mite Allergy - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 53 Pages
簡介

塵蟎過敏是指對一般棲息在室內灰塵中的蟎蟲有過敏反應,造成噴嚏和鼻涕、鼻塞、鼻子癢、眼請疼痛等症狀。也有可能成為氣喘及混疹的契機,一接近揚起的塵蟎容易惡化。家族病史及年齡是致病原因,治療方法有使用抗組織胺藥物,充血緩和劑,皮質類固醇等。

本報告涵括全球塵蟎過敏治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品評估等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

塵蟎過敏概要

治療藥的開發

  • 塵蟎過敏開發中產品:概要
  • 塵蟎過敏開發中產品:比較分析

塵蟎過敏:正在開發的治療藥:各企業

塵蟎過敏:正在開發的治療藥:大學·研究機關別

塵蟎過敏:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

塵蟎過敏:開發中的產品:各企業

塵蟎過敏:開發中的產品:大學·研究機關別

塵蟎過敏:開發治療藥的企業

  • ALK-Abello A/S
  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Stallergenes S.A.

塵蟎過敏:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AllerDM
  • Allergen for House Dust Mite Allergy
  • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis
  • BM-35
  • MK-8237
  • PL-103
  • STG-320
  • Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8254IDB

Summary

Global Markets Direct's, 'House Dust Mite Allergy - Pipeline Review, H2 2016', provides an overview of the House Dust Mite Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy
  • The report reviews pipeline therapeutics for House Dust Mite Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved House Dust Mite Allergy therapeutics and enlists all their major and minor projects
  • The report assesses House Dust Mite Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for House Dust Mite Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • House Dust Mite Allergy Overview
  • Therapeutics Development
    • Pipeline Products for House Dust Mite Allergy - Overview
  • House Dust Mite Allergy - Therapeutics under Development by Companies
  • House Dust Mite Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • House Dust Mite Allergy - Products under Development by Companies
  • House Dust Mite Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Anergis SA
    • Biomay AG
    • Circassia Pharmaceuticals Plc
    • HAL Allergy BV
    • Stallergenes SAS
  • House Dust Mite Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AllerDM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-35 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • House Dust Mite Allergy - Dormant Projects
  • House Dust Mite Allergy - Discontinued Products
  • House Dust Mite Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX
      • Apr 13, 2016: License application for investigational house dust mite SLIT-tablet accepted for review by FDA
      • Apr 12, 2016: Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet
      • Jan 27, 2016: Marketing authorisation for ACARIZAX issued in France
      • Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark
      • Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan
      • Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan
      • Jun 09, 2015: ALK's partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal
      • Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet
      • Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet
      • Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study
      • Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet
      • Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development
      • Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet
      • Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for House Dust Mite Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H2 2016
  • House Dust Mite Allergy - Pipeline by Anergis SA, H2 2016
  • House Dust Mite Allergy - Pipeline by Biomay AG, H2 2016
  • House Dust Mite Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • House Dust Mite Allergy - Pipeline by HAL Allergy BV, H2 2016
  • House Dust Mite Allergy - Pipeline by Stallergenes SAS, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • House Dust Mite Allergy - Dormant Projects, H2 2016
  • House Dust Mite Allergy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for House Dust Mite Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top